An experimental malaria vaccine developed by GlaxoSmithKline Plc has reduced the risk of malaria by half in African children between the ages of five and 17 months. The results have been published in the New England Journal of Medicine.
Oxford BioMedica Plc has received approval from the US Food and Drug Administration to start a first human study of its gene therapy for Usher syndrome, a genetic disorder that affects hearing and vision. The study will take place in Oregon.
The European regulatory review of SkyePharma Plc’s asthma treatment, Flutiform, will take longer than originally anticipated due to a lack of complete consensus among the member states about the product, SkyePharma announced on 18 October.
NeoStem Inc of New York, which has a business in adult stem cell collection and storage, has completed an all-share acquisition of Amorcyte Inc of New Jersey in a bid to develop a portfolio of therapies based on stem-cell technology.
The Roche group has reached an agreement to acquire Anadys Pharmaceuticals Inc for $230 million in order to expand its franchise in treatments for hepatitis C virus (HCV) infections. Anadys is located in San Diego, California.
Wilex AG was boosted in the first nine months of 2011 by income from a licensing agreement for its lead cancer antibody with Prometheus Laboratories Inc (Nestle SA). Nine-month income was €5.6 million compared with €1.2 million a year earlier.
The Roche group has confirmed its earnings forecast for 2011 of core earnings per share growth of about 10% at constant exchange rates. Sales for the first nine months declined in Swiss francs and were flat at constant exchange rates.
Phase 2 data from the immunotherapy, talactoferrin, for non-small cell lung cancer have been published in the Journal of Clinical Oncology. The data showed an improvement in overall survival of patients who were treated with the drug.
Affiris AG of Austria has received $1.5 million from the Michael J. Fox Foundation in the US to start a Phase 1 study of a new vaccine for Parkinson’s disease. The therapeutic vaccine candidate targets the protein, alpha-synuclein.
Pevion Biotech AG said that data from an ongoing first-in-human trial of a therapeutic vaccine against Candida in healthy volunteers elicited high levels of specific antibodies and a 100% mucosal immune response rate.